Page 4 - Nathan Kaiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team — Kite, a Gilead Company today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors. “Franco’s proven track … — Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team...

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Throug...

(2) Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005129/en/ Through this collaboration, OBT will validate five novel oncology drug targets, previously identified usin...

Posted on 10654 Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Conditional authorization is granted in the interest of public health where the...

(2) -- 93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus -- -- Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe -- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two o...